Liquidia Technologies (LQDA)
(Delayed Data from NSDQ)
$15.07 USD
-0.85 (-5.34%)
Updated Mar 27, 2024 04:00 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
Liquidia Technologies, Inc. [LQDA]
Reports for Purchase
Showing records 1 - 20 ( 126 total )
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
FDA Adds Fuel to the Fire, Extends YUTREPIA NDA Review Amid Ongoing Litigation
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
David Goliath Showdown Continues: Federal Circuit Affirms ''793 PTAB Decision
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Federal Circuit Affirms ''793 PTAB Decision; Tyvaso DPI''s Dominance to Persist
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for LQDA 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Q3: Another Layer of Patent Litigation Added to the Ongoing Battle with United
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Near-Term Sights on 793 Patent and Federal Circuit-Potential Yutrepia Expansion; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Q2: Twists Turns Added to the Litigation Labyrinth, Launch Timing Unclear
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Ongoing Yutrepia Litigation for 793 Patent-Remaining Gating to Approval; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Patent Battle is Likely Far From Over Despite H-W Ruling Affirmed on Appeal
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Taking Another Shot on the PAH/PH-ILD Goal with Pharmosa''s Treprostinil Product
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Litigation Updates, Potential Launch Timeline Remains Intact; Q1:23 Financials
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Yutrepia Progress and Interpreting Near-Term Litigation Scenarios; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A